Celldex Therapeutics (CLDX) Stock Price, Quote & News

Company Profile

Celldex Therapeutics, Inc., a biopharmaceutical company, engages in developing therapeutic antibodies for patients with severe inflammatory, allergic, autoimmune, and other diseases. The company's drug candidates include monoclonal and bispecific antibodies designed to address mast cell mediated diseases for which available treatments are inadequate. Its clinical development programs are Barzolvolimab (CDX-0159), a monoclonal antibody that specifically binds the KIT receptor and potently inhibit...

Industry: Biotechnology

Sector: Healthcare

Phone: 908 200 7500

Fax: 908 454 1911

Website: www.celldex.com

Address:

Perryville III Building, Suite 220 53 Frontage Road, Hampton, United States

Ccg_ Aug. 6 at 2:26 PM

$CLDX what is going on with this turd?

0 · Reply

Steve1545 Aug. 5 at 7:44 PM

$CLDX point72 showing how easy they can bid it back up?

0 · Reply

TheGunnerAB Aug. 1 at 4:11 PM

$CLDX @RonIsWrong Steven Cohen still holding 10,000 August $22 5 call he paid $3 each or $3M in total premium. The company didn't announce ER date yet, weird. Last quarter they reported on 5/8.

1 · Reply

Prosperity1_ Aug. 1 at 2:43 PM

$CLDX I keep on beating this drum. The 2+ year lag in submitting to the FDA is absolutely absurd. It painful to see that no one is questioning this or putting pressure on the CEO for an improved timeline. This is the reason why this stock will never rise to anywhere near anyone's including all the analysts projections. I prove my point with CELC. I know everyone thinks I am a basher or shorter but NO, I am just a foolish investor that is in this at $9/share and hate being fooled by hype from a pumper CEO. It's bad for shareholders but worse for those with this cancer praying for a cure. It's all on me for missing critical aspects of the company. When buying small promising biotechs, every single stone must be turned. CELC had positive Phase 3 results last week and will be submitting to the FDA on December, yes, December 2025.

1 · Reply

FiveStarStocks Jul. 30 at 1:01 AM

$CLDX Holding

0 · Reply

CrispDry Jul. 28 at 8:44 PM

$CLDX does this even have a pulse anymore?

1 · Reply

Steve1545 Jul. 24 at 1:21 PM

$CLDX

2 · Reply

CrispDry Jul. 23 at 2:40 PM

$CLDX is there any news?

1 · Reply

Steve1545 Jul. 23 at 12:05 PM

$CLDX

1 · Reply

svertical1 Jul. 22 at 2:13 PM

$IBRX Yervoy, but would still work better as combo with Anktiva. The back story is one we all know too well. Yervoy & Optivo 2024 Rev- now 12 B $BMY bought $MEDX (old $CLDX) for 2.4 billion - they got Yervoy and Nivolumab (Optivo), a steal. Thankfully, PSS knows this game well.

2 · Reply

Celldex Presents Data Demonstrating Profound Long Term Improvement in Angioedema in Barzolvolimab Phase 2 Study in Chronic Spontaneous Urticaria at EAACI 2025

Jun 12, 2025, 6:01 PM EDT - 7 weeks ago

Celldex Presents Unprecedented 76 Week Results from Barzolvolimab Phase 2 Study in Chronic Spontaneous Urticaria at EAACI Congress 2025

Jun 10, 2025, 4:01 PM EDT - 2 months ago

Celldex Announces Upcoming Presentations of Barzolvolimab Phase 2 Data in Chronic Spontaneous Urticaria at EAACI 2025 Congress

Jun 6, 2025, 8:01 AM EDT - 2 months ago

Celldex Therapeutics Announces Election of Denice Torres to its Board of Directors

May 8, 2025, 4:01 PM EDT - 3 months ago

Celldex Reports First Quarter 2025 Financial Results and Provides Corporate Update

May 5, 2025, 4:01 PM EDT - 3 months ago

Celldex Presents Histology Data from Phase 2 Study of Barzolvolimab in EoE Supporting Potential of Mast Depleting Agent in this Difficult to Treat Disease

Mar 4, 2025, 8:01 AM EST - 5 months ago

Celldex Therapeutics to Present at Upcoming Investor Conferences

Mar 3, 2025, 8:01 AM EST - 5 months ago

Celldex Therapeutics Presents Positive Preclinical Data from Inflammatory Bispecific Antibody Program CDX-622 at AAAAI 2025

Mar 1, 2025, 12:45 PM EST - 5 months ago

Celldex Therapeutics Presents Positive Results from Barzolvolimab Phase 2 Studies in Patients with Chronic Urticaria Demonstrating Improved Disease Control and Quality of Life at AAAAI 2025

Feb 27, 2025, 4:01 PM EST - 5 months ago

Celldex Reports Fourth Quarter and Year End 2024 Financial Results and Provides Corporate Update

Dec 19, 2024, 8:01 AM EST - 8 months ago

Celldex Initiates Phase 2 Study of Barzolvolimab in Atopic Dermatitis

Nov 20, 2024, 8:01 AM EST - 9 months ago

Celldex Announces First Patient Dosed in Phase 1 Healthy Volunteer Study of CDX-622, a Bispecific Antibody, for the Treatment of Inflammatory Diseases

Nov 6, 2024, 4:01 PM EST - 9 months ago

Celldex Reports Third Quarter 2024 Financial Results and Provides Corporate Update

Nov 4, 2024, 3:14 PM EST - 9 months ago

Celldex Therapeutics' Strong Cash Runway Supports Barzolvolimab's Path To Market

Oct 26, 2024, 5:43 PM EDT - 10 months ago

Celldex Announces Barzolvolimab Met All Primary and Secondary Endpoints with High Statistical Significance in Positive Phase 2 Study in Chronic Inducible Urticaria

Oct 25, 2024, 8:01 AM EDT - 10 months ago

Celldex Announces Upcoming Late Breaking Oral Presentation of 12 Week Results from Barzolvolimab Phase 2 Study in Chronic Inducible Urticaria at ACAAI 2024

Sep 25, 2024, 10:45 AM EDT - 11 months ago

Celldex Therapeutics Presents Landmark 52 Week Results from Barzolvolimab Phase 2 Study in Chronic Spontaneous Urticaria at EADV 2024

Sep 16, 2024, 8:01 AM EDT - 11 months ago

Celldex Announces Upcoming Late Breaking Oral Presentation of 52 Week Results from Barzolvolimab Phase 2 Study in Chronic Spontaneous Urticaria at EADV Congress 2024

Aug 8, 2024, 4:01 PM EDT - 1 year ago

Celldex Reports Second Quarter 2024 Financial Results and Provides Corporate Update

Jul 29, 2024, 4:01 PM EDT - 1 year ago

Celldex Therapeutics Presents Positive Topline Results from Barzolvolimab Phase 2 Study in Chronic Inducible Urticaria

Jul 16, 2024, 8:01 AM EDT - 1 year ago

Celldex Therapeutics Initiates Global Phase 3 Program for Barzolvolimab in Patients with Chronic Spontaneous Urticaria

Jun 4, 2024, 4:01 PM EDT - 1 year ago

Celldex Therapeutics to Present at Jefferies Healthcare Conference

Jun 2, 2024, 9:01 AM EDT - 1 year ago

Celldex Therapeutics Presents Data Demonstrating Profound Improvements in Angioedema in Barzolvolimab Phase 2 Study in Chronic Spontaneous Urticaria at EAACI 2024

May 15, 2024, 8:01 AM EDT - 1 year ago

Celldex Announces First Patient Dosed in Phase 2 Study of Barzolvolimab in Prurigo Nodularis

May 10, 2024, 10:44 AM EDT - 1 year ago

Celldex Therapeutics: Rising High, With Room For Further Growth

May 6, 2024, 4:01 PM EDT - 1 year ago

Celldex Reports First Quarter 2024 Financial Results and Provides Corporate Update

Apr 17, 2024, 8:01 AM EDT - 1 year ago

Celldex Announces Completion of Enrollment in Phase 2 Study of Barzolvolimab in Patients with Chronic Inducible Urticaria

Mar 8, 2024, 7:00 AM EST - 1 year ago

Celldex Therapeutics to Participate in the Leerink Partners Global Biopharma Conference

Mar 5, 2024, 10:30 AM EST - 1 year ago

Celldex Therapeutics to Present at TD Cowen's 44th Annual Health Care Conference

Mar 5, 2024, 10:10 AM EST - 1 year ago

Celldex Therapeutics Announces Closing of Public Offering of Common Stock and Full Exercise of Underwriters' Option to Purchase Additional Shares

Feb 29, 2024, 9:14 PM EST - 1 year ago

Celldex Therapeutics Announces Pricing of Upsized $400 Million Public Offering of Common Stock

Feb 28, 2024, 4:01 PM EST - 1 year ago

Celldex Therapeutics Announces Proposed Public Offering of Common Stock

Feb 26, 2024, 7:01 AM EST - 1 year ago

Celldex Reports Fourth Quarter and Year End 2023 Financial Results and Provides Corporate Update

Feb 24, 2024, 2:05 PM EST - 1 year ago

Celldex Therapeutics Presents Positive 12 Week Results from Barzolvolimab Phase 2 Study in Chronic Spontaneous Urticaria

Feb 6, 2024, 4:01 PM EST - 1 year ago

Celldex to Participate in the Guggenheim Healthcare Talks 6th Annual Biotechnology Conference

Feb 5, 2024, 8:01 AM EST - 1 year ago

Celldex Announces Upcoming Presentation of Barzolvolimab Phase 2 Results in Chronic Spontaneous Urticaria at AAAAI 2024

Jan 29, 2024, 10:45 AM EST - 1 year ago

MoneyShow's Best Investment Ideas For 2024: Part 3

CFR CHRD CROX CTO GLW LEU SCHW

Jan 26, 2024, 5:30 PM EST - 1 year ago

MoneyShow's Best Investment Ideas For 2024: Part 2

ANET BAX BIP BLK BP CCJ CSTE

Nov 27, 2023, 4:15 PM EST - 1 year ago

Celldex Therapeutics to Present at 6th Annual Evercore ISI HealthCONx Conference

Nov 8, 2023, 3:22 PM EST - 1 year ago

Celldex: Mast Cell Disease Targeting Continues To Make Advancements In Clinic

Nov 7, 2023, 11:15 PM EST - 1 year ago

Celldex Therapeutics Announces Pricing of Public Offering of Common Stock

Nov 6, 2023, 8:15 AM EST - 1 year ago

Celldex Therapeutics shares surge as lead asset shows promise in two skin conditions

Nov 6, 2023, 6:30 AM EST - 1 year ago

Celldex Therapeutics Announces Positive Topline Results from Barzolvolimab Phase 2 Study in Chronic Spontaneous Urticaria

Nov 5, 2023, 3:00 PM EST - 1 year ago

Celldex Therapeutics Presents Positive Data from Prurigo Nodularis Phase 1b Study Demonstrating Meaningful Reduction in Itch and Skin Clearing with Single Dose 3.0 mg/kg Barzolvolimab

Nov 2, 2023, 4:01 PM EDT - 1 year ago

Celldex Reports Third Quarter 2023 Financial Results and Provides Corporate Update

Sep 26, 2023, 7:01 AM EDT - 2 years ago

Celldex Announces Acceptance of Abstract for Barzolvolimab Phase 1b Results in Prurigo Nodularis at 12th World Congress on Itch (WCI) 2023

Sep 25, 2023, 8:31 AM EDT - 2 years ago

Celldex Therapeutics to Present at Cantor Global Healthcare Conference

Aug 11, 2023, 8:41 AM EDT - 2 years ago

Celldex Therapeutics: Promising Phase 1b Results For Barzolvolimab In CSU

Aug 8, 2023, 4:01 PM EDT - 2 years ago

Celldex Reports Second Quarter 2023 Financial Results and Provides Corporate Update

Jul 11, 2023, 8:01 AM EDT - 2 years ago

Celldex Announces Completion of Enrollment in Phase 2 Study of Barzolvolimab in Patients with Chronic Spontaneous Urticaria

Ccg_ Aug. 6 at 2:26 PM

$CLDX what is going on with this turd?

0 · Reply

Steve1545 Aug. 5 at 7:44 PM

$CLDX point72 showing how easy they can bid it back up?

0 · Reply

TheGunnerAB Aug. 1 at 4:11 PM

$CLDX @RonIsWrong Steven Cohen still holding 10,000 August $22 5 call he paid $3 each or $3M in total premium. The company didn't announce ER date yet, weird. Last quarter they reported on 5/8.

1 · Reply

Prosperity1_ Aug. 1 at 2:43 PM

1 · Reply

FiveStarStocks Jul. 30 at 1:01 AM

$CLDX Holding

0 · Reply

CrispDry Jul. 28 at 8:44 PM

$CLDX does this even have a pulse anymore?

1 · Reply

Steve1545 Jul. 24 at 1:21 PM

$CLDX

2 · Reply

CrispDry Jul. 23 at 2:40 PM

$CLDX is there any news?

1 · Reply

Steve1545 Jul. 23 at 12:05 PM

$CLDX

1 · Reply

svertical1 Jul. 22 at 2:13 PM

2 · Reply

svertical1 Jul. 22 at 12:44 PM

$IBRX $BMY $CLDX $MEDX A blast from the past from ‘sogenerous’. These 2 drugs have 2024 sales of nearly 12 Billion. Medarex was bought by BMY for net 2.1B, BP played same games even then. Should’ve been 10X that price minimum.

1 · Reply

TheGunnerAB Jul. 21 at 3:44 PM

$CLDX it sure looks like what's where this is heading. I'm not sure what his logic was buying 10K of the August $22.5 calls for $3 on top of the shares he bought at the open market. He should have waited and bought more shares at the open market under $23. He's a billionaire and I'm not. I guess we will see.

1 · Reply

Messerschmittbf109 Jul. 19 at 5:09 AM

$JSPR $CLDX Jasper's main competitor in the c-Kit inhibitor space is Celldex Therapeutics (NASDAQ:CLDX) with its drug barzolvolimab. Analysts have made comparisons between the two companies, noting that Celldex's market capitalization is about six times that of Jasper's, suggesting a potential upside for JSPR if briquilimab demonstrates competitive or superior efficacy and safety profiles…..

0 · Reply

TheGunnerAB Jul. 18 at 4:36 PM

$CLDX will Steven Cohen of Point72 will let his 10K August $22.5 calls expire worthless. He spent $3M on those. Four more weeks to go from today.

1 · Reply